Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating tumour DNA (ctDNA) analysis to improve testing and treatment for oncologists and their patients.
Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free DNA (ctDNA) which can be collected through a simple blood sample.
This minimally-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated. The test allows precise analysis of cancer-related mutations present in ctDNA, and is designed to provide oncologists with clinically actionable genomic information to guide therapy selection, monitor treatment progress and detect new mutations as they emerge.
Inivata was spun out from Cancer Research UK in 2014 and launched with £4.0 million in funding from Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation. In 2016 Inivata raised a further £31.5m Series A round, Woodford Investment Management, joining the investment syndicate.